



Call for Submissions




Advances in Laboratory Medicine/Avances en Medicina de Laboratorio

Theme Issue: Biochemical bone markers: new aspects in analytical issues and application in disease

Advances in Laboratory Medicine/Avances en Medicina de Laboratorio (Adv Lab Med) is pleased to announce a call for submissions for a special thematic issue on **Biochemical bone markers: new aspects in analytical issues and application in disease**, which is scheduled for publication in September 2023. **The submission deadline is June 30, 2023.**

About *Advances in Laboratory Medicine/Avances en Medicina de Laboratorio*

- The official journal of SEQC^{ML} (Sociedad Española de Medicina de Laboratorio)
- Listed in the Web of Science (ESCI), PMC, Scopus and other major A & I services
- Peer-reviewed and led by a multi-institutional editorial board
- Focused on fundamental and applied research and cutting-edge clinical laboratory medicine
-  Published Open Access articles under the [Creative Commons Attribution \(CC-BY-4.0\) License](https://creativecommons.org/licenses/by/4.0/). All articles will be funded by an unrestricted educational grant, and authors will not be charged with article processing charges. The grant will play no role in the selection and publication of the articles, nor will it influence peer review.
- Published by De Gruyter, an international, independent scientific publisher

Bone is undergoing continuous remodelling to maintain mechanical capacities, repair damage and maintain bone homeostasis. This process is carried out through osteoclastic and osteoblastic activity of bone resorption and bone formation, respectively. This balance in bone remodelling can be altered in various pathological situations, some of which are very prevalent, such as osteoporosis or chronic kidney disease. Imaging and analytical methods have been developed for its evaluation. There are various biochemical markers produced by this osteoblastic and osteoclastic activity that provide dynamic information on bone turnover. Typical resorption markers include degradation products of collagen molecules or tartrate-resistant alkaline phosphatase, while formation markers reflecting osteoblastic activity include collagen or bone matrix synthesis molecules. These biomarkers have been determined in circulation and urine and have shown unequal sensitivity and specificity in bone pathology and treatment monitoring. There are pre-analytical factors and analytical and biological variability that influence the interpretation of the results. Furthermore, harmonized measurement systems and appropriate reference values are needed. Therefore, in this special issue we encourage papers that discuss the current status of biochemical study in bone pathology and treatment monitoring, as well as its integration with other imaging tests.

In this Special Issue we encourage authors to submit papers that discuss the current state of biochemical investigation in bone pathology and treatment monitoring, and its integration with other imaging tests.

The *Adv Lab Med* website (<https://www.degruyter.com/almed>) outlines:

- Author information (with article types & word limits)
<https://www.degruyter.com/journal/key/almed/html>
- Submission system: <http://mc.manuscriptcentral.com/almed>

Articles can be submitted in either English or Spanish. All manuscripts will be translated into Spanish or English at no cost to the authors.

Prospective authors are encouraged to notify the issue editors Dr. Álvaro González (agonzaleh@unav.es) and Pilar Fernández-Calle (pfernandez.hulp@gmail.com) of their intent to submit articles. Final article submissions are due by **June 30, 2023**.

Please reference the “Bone Marker Special Issue” in your cover letter.

All manuscripts will undergo the standard editorial and peer review process for papers submitted to *Adv Lab Med*. All articles will be published immediately after acceptance. Research articles, reviews and short communications are particularly welcome.

If you have any questions, please contact the editorial office (editorial.office@seqc.es).